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Purpose: In this study, we compared the treatment outcomes for an α-blocker between 2 groups of men, one with high sym-
pathetic activity (HSA) and another with low sympathetic activity (LSA) or normal sympathetic activity. 
Methods: A total of 159 men (≥50 years of age) with lower urinary tract symptoms resulting from benign prostatic hyperpla-
sia were analyzed. We assigned patients to groups according to their sympathetic activity, which was evaluated by heart rate 
variability measurements. HSA was defined as a low frequency/high frequency ratio greater than 1.6. All patients received 10 
mg of alfuzosin once a day for 12 weeks. The primary end point was a change in the total International Prostate Symptom 
Score (IPSS) at 12 weeks from baseline. 
Results: Sixty-seven men were assigned to the HSA group and 92 men were assigned to the LSA group. The baseline charac-
teristics were not significantly different between the 2 groups, and the response to alfuzosin was good in both groups. The 
mean total IPSS change was not different between the groups. Both groups were not significantly different with respect to the 
changes in maximal flow rate, IPSS voiding or storage symptom subscores, quality of life, and rates of adverse drug events. The 
HSA group showed a similar willingness to continue treatment compared to the LSA group, although their treatment satisfac-
tion rating was lower. 
Conclusions: The therapeutic effects of alfuzosin did not differ in regards to the differences in sympathetic activity, but treat-
ment satisfaction ratings were lower in the HSA group. 
Keywords: Heart Rate; Prostatic Hyperplasia; Sympathetic Nervous System; Lower Urinary Tract Symptoms
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INTRODUCTION 
Benign prostate hyperplasia (BPH) is a disease primarily preva-
lent in elderly men. Many of individuals with BPH have lower 
urinary tract symptoms (LUTS) that hinder general activity and 
deteriorate quality of life (QoL) [1,2]. Although transurethral 
surgery can provide effective relief, medical treatment with 
careful follow-up is the first-line treatment strategy for BPH [3]. 
Alpha-blockers relieve bladder outlet obstruction through the 
smooth muscle relaxation in the prostate, prostatic capsule, 
base, and trigone of the bladder [3,4], and are an effective and 
rapid available treatment [5]. Previous studies have argued that 
LUTS in males is associated with sympathetic nervous system 
activity. Sympathetic overactivity has been associated with more 
rapid BPH development [6], while autonomic nervous system 
(ANS) hyperactivity is also significantly associated with LUTS 
[7]. Choi et al. [8] have argued that men with LUTS have higher 
sympathetic activity, and of those individuals, men with void-
ing symptom-predominant LUTS have relatively higher sym-
pathetic activity than men with storage symptom-predominant 
LUTS. Since these differences in sympathetic activity are associ-
ated with differences in LUTS, α-blocker treatment outcomes 
may also be different, depending on sympathetic activity. 
 There are many methods that can be used to evaluate auto-
nomic activity, including measuring the Valsalva ratio or per-
forming a tilt-table or thermoregulatory sweat test [9]. The 
measurement of heart rate variability (HRV) is also a well-es-
tablished noninvasive assessment tool that can be used to evalu-
ate autonomic nervous activity [10]. 
 In this study, we used HRV measurements to compare treat-
ment outcomes of an α-blocker for LUTS in men with in-
creased sympathetic activity compared to men with normal or 
lower sympathetic activity. 
MATERIALS AND METHODS
Patients and Study Design 
This prospective, multicenter, open-labeled observational study 
was conducted in 11 hospitals in Korea. The study protocol was 
reviewed and approved by The Institutional Review Board of 
each study center. The enrolled patients suffered from LUTS as-
sociated with BPH and were deemed to be fit for α-blocker 
treatment based on the decision of their physicians. The inclu-
sion criteria included age ≥50 years old, total International 
Prostate Symptom Score (IPSS) ≥8, maximum urinary flow 
rate (Qmax)≤15 mL/sec, and a period of more than 3 months 
with LUTS. Subjects with the following conditions were exclud-
ed from the study: allergic drug reaction to α-blockers, ortho-
static hypotension, a history of prostatectomy, renal impair-
ment, severe hepatic disorders, a prostate-specific antigen level 
higher than 10 ng/mL, the use of any α-blocker in the 4 weeks 
prior to baseline measurements, or the use of 5 alpha-reductase 
inhibitors in the 6 months prior to baseline measurements. Pa-
tients who were currently receiving or were planning to take 
the following drugs that could influence ANS were excluded: α- 
or β-receptor agonists or antagonists, anticholinergics, antihy-
pertensive drugs, antipsychotics, anxiolytics, or antidepressants. 
 The primary end point of the study was the change in total 
IPSS at 12 weeks from baseline. The secondary endpoints includ-
ed changes in IPSS subscores, QoL, Qmax, and postvoid residual 
(PVR) volume ratio (residual volume/[voided volume+residual 
volume]) at 12 weeks, and a benefit, satisfaction with treatment, 
and willingness to continue treatment questionnaire (BSW) [11] 
at 12 weeks. 
 After screening, HRV parameters were measured using an 
in-house system, according to the standard methods described 
in previous studies [8,10]. Consumption of food, tea, or coffee 
and cigarette smoking before the HRV measurement were re-
stricted in order to avoid any potential influence on the ANS. 
After 30 minutes of rest, each patient underwent an electrocar-
diographic signal recording for 5 minutes while sitting (SA-
3000P, Medicore, Seoul, Korea). We found that the mean value 
of the low frequency/high frequency (LF/HF) ratio in healthy 
elderly men was approximately 1.6, using data from a pilot 
study of 118 healthy volunteers (40–70 years of age) who had a 
total IPSS lower than 8. Therefore, patients with an LF/HF ra-
tio≥1.6 were assigned to the high sympathetic activity (HSA) 
group, while those with an LF/HF lower than 1.6 were assigned 
to the low sympathetic activity (LSA) group. 
 All patients were given 10 mg of alfuzosin once a day for 12 
weeks. The IPSS and QoL scores, Qmax, PVR, overactive blad-
der symptom score (OAB-SS), and simplified International In-
dex of Erectile Function (IIEF-5) were assessed at 4 and 12 
weeks. BSW was obtained at 12 weeks. State anxiety and trait 
anxiety were evaluated using the Korean version of the Spiel-
berger State Trait Anxiety Inventory [12] at baseline and at 12 
weeks. All adverse events and adverse drug reactions were re-
corded and assessed for severity and causal relationship. 
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Statistical Analysis
The Student t-test and Wilcoxon rank sum test were used to 
analyze continuous variables, and the chi-square test was used 
to analyze the categorical variables. For variables that differed at 
baseline, the analysis of covariance test was performed to com-
pare 2 groups. All results are expressed as the mean±standard 
deviation. All statistical evaluations were performed using IBM 
SPSS Statistics ver. 19.0 (IBM Co., Armonk, NY, USA). A P-val-
ue of less than 0.05 was considered to be significant. 
RESULTS
Between June 2011 and February 2013, 159 patients were assigned 
to the HSA group (n=67) or to the LSA group (n=92), according 
to their LF/HF ratio (Fig. 1). The baseline characteristics of both 
groups are presented in Table 1. The HSA and LSA groups did not 
differ in mean age (60.0±5.8 and 62.5±7.9 years, respectively, 
P=0.061), mean body mass index (23.7±2.5 and 23.3±2.6 kg/
m2, respectively, P=0.476), IIEF-5 (12.9±6.6 and 14.1±7.6, re-
spectively, P=0.219) and total IPSS (16.8±6.2 and 16.6±6.5, re-
spectively, P=0.741). However, the HSA and LSA groups differed 
in QoL (4.0±0.8 and 3.6±1.1, respectively, P=0.045), Qmax 
(9.2±3.6 and 11.3±4.5 mL/sec, respectively, P=0.001), and PVR 
(22.0±25.1 and 36.6±36.7 mL, respectively, P=0.007) (Table 1). 
Alfuzosin treatment induced a significant improvement in LUTS 
for both groups. The total changes for IPSS at 4 weeks were 
–3.63±5.19 in the HSA group and –2.92±6.32 in the LSA group. 
The Qmax improvements were 2.34±5.07 in the HSA group and 
2.29±4.80 in the LSA group. After 12 weeks of treatment, the 
mean total IPSS change in the HSA group did not differ from the 
LSA group (–3.67±5.61 and –3.88±6.04, respectively, P=0.817). 
The HSA and LSA groups did not differ on the following parame-
ters: changes in Qmax (3.31±6.42 and 2.63±6.39, respectively, 
P=0.880), PVR ratio (–1.81%±8.84% and –2.95%±12.18%, re-
spectively, P =0.912), IPSS voiding symptom subscore 
(–2.52±4.23 and –2.48±4.51, respectively, P=0.964), IPSS stor-
age symptom subscore (–1.15±2.08 and –1.40±2.33, respectively, 
P =0.694), QoL (–0.45 ±0.97 and –0.51 ±1.29, respectively, 
P=0.204), OAB-SS (–0.40±1.29 and –0.17±1.51, respectively, 
P=0.549), and rates of adverse drug events (13.2% and 9.7%, re-
spectively, P=0.479). The HSA group showed slightly more im-
provement in changes in IIEF-5 compared to the LSA group 
(1.14±5.34 and –0.71±5.04, respectively, P=0.049). The changes 
in state anxiety (HSA, –1.42±5.28; LSA, –1.76±6.64, P=0.837) 
Table 1. Baseline characteristics    
Characteristic HSA group (n=67) LSA group (n=92) P-value
Age (yr) 60.0±5.8 62.5±7.9 0.061
Body mass index (kg/m2) 23.7±2.5 23.3±2.6 0.476
LF/HF ratio 3.97±4.52 0.91±0.4 <0.001
IPSS total
 Voiding subscore
 Storage subscore
16.8±6.2
10.4±4.3
6.4±3.1
16.6±6.5
10.2±4.9
6.5±3.1
0.741
0.665
0.718
Quality of life 4.0±0.8 3.6±1.1 0.045
Qmax (mL/sec) 9.2±3.6 11.3±4.5 0.001
Postvoid residual (mL) 22.0±25.1 36.6±36.7 0.007
Values are presented as mean±standard deviation.   
HSA, high sympathetic activity; LSA, low sympathetic activity; LF/HF, low frequency/high frequency; IPSS, International Prostate Symptom Score; 
Qmax, maximum urinary flow rate.   
Fig. 1. Patient disposition. HRV, heart rate variability.
2 Withdrawal of consent
4 Violated eligible criteria
169 Screened
163 Enrolled
4 Follow-up loss
67 High sympathetic  
activity
92 Low sympathetic  
activity
Follow-up data acquisition after 
12-week medication with 
α-blocker
Baseline data 
acquisition HRV test
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and changes in trait anxiety (HSA, –0.46±5.67; LSA, –1.73±5.69; 
P=0.284) did not differ between the groups (Table 2). With re-
spect to BSW, the HSA group reported that they received a similar 
benefit (HSA, 74.2%; LSA, 83.9%; P=0.243) and had a similar 
willingness to continue treatment (HSA, 76.7%; LSA, 90.1%; 
P=0.053) compared to the LSA group. However, treatment satis-
faction ratings in the HSA group were lower than the LSA group 
(HSA, 72.1%; LSA, 87.7%; P=0.049). 
DISCUSSION
The dynamic component yields great importance in the pathol-
ogy of BPH. Although the prostate size is not related to the se-
verity of BPH symptoms [13], urethral obstruction is directly 
correlated with the amount of prostatic smooth muscle [14]. 
The prostate is innervated by both the sympathetic and para-
sympathetic nervous systems [15]. Sympathetic innervation is 
essential to the regulation of stromal cells and may provide 
Table 2. Changes of clinical characteristics from baseline after 12 weeks of treatment    
Variable HSA group (n=67) LSA group (n=92) P-value
IPSS total
 Baseline
 Change from baseline
  
16.8±6.2
–3.67±5.61
  
16.6±6.5
–3.88±6.04
  
0.741
0.817
Voiding subscore
 Baseline
 Change from baseline
  
10.4±4.3
–2.52±4.23
  
10.2±4.9
–2.48±4.51
  
0.665
0.964
Storage subscore
 Baseline
 Change from baseline
  
6.4±3.1
–1.15±2.08
  
6.5±3.1
–1.40±2.33
  
0.718
0.694
Quality of life
 Baseline
 Change from baseline
  
4.0±0.8
–0.45±0.97
  
3.6±1.1
–0.51±1.29
  
0.045
0.204
Qmax (mL/sec)
 Baseline
 Change from baseline
  
9.2±3.6
3.31±6.42
  
11.3±4.5
2.63±6.39
  
0.001
0.880
Ratio of PVR (%)
 Baseline
 Change from baseline
  
11.6±11.7
–1.81±8.84
  
15.0±15.1
–2.95±12.18
  
0.174
0.912
PVR (mL)
 Baseline
 Change from baseline
  
22.0±25.1
–0.03±25.24
  
36.6±36.7
–9.86±29.81
  
0.007
0.530
IIEF-5
 Baseline
 Change from baseline
  
12.9±6.6
1.14±5.34
  
14.1±7.6
–0.71±5.04
  
0.219
0.049
OAB-SS
 Baseline
 Change from baseline
  
3.9±2.4
–0.40±1.29
  
3.5±2.1
–0.17±1.51
  
0.310
0.549
STAI - state anxiety
 Baseline
 Change from baseline
  
40.8±10.0
–1.42±5.28
  
39.5±10.8
–1.76±6.64
  
0.447
0.837
STAI - trait anxiety
 Baseline
 Change from baseline
  
41.1±9.7
–0.46±5.67
  
41.3±11.1
–1.73±5.69
  
0.903
0.284
Values are presented as mean±standard deviation.   
HSA, high sympathetic activity; LSA, low sympathetic activity; IPSS, International Prostate Symptom Score; Qmax, maximum urinary flow rate; 
PVR, postvoid residual; IIEF-5, International Index of Erectile Function; OAB-SS, overactive bladder symptom score; STAI, state-trait anxiety inven-
tory.    
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prostatic muscle tone. Alpha-adrenergic receptors are concen-
trated in stromal cells and in the prostatic blood vessels [15]. 
Prostate growth is also associated with autonomic nervous ac-
tivity. In a study with aging rats, autonomic activity increases 
facilitated the development of prostatic hyperplasia; removal of 
this innervation resulted in a regression in prostate gland 
weight [16]. Many previous studies have suggested an associa-
tion between elevated sympathetic activity and BPH with 
LUTS, such that more rapidly developing BPH is associated 
with sympathetic overactivity [6]. Meigs et al. [17] showed that 
sympathetic activation, as measured by increased serum mark-
ers of heart disease and increased β-blocker use, is associated 
with symptomatic BPH. McVary et al. [7] evaluated various 
markers of ANS activity in men who had BPH with LUTS, and 
reported that ANS hyperactivity was associated with LUTS se-
verity and prostate size. 
 There are many methods to evaluate ANS activity, and analy-
sis of HRV is one of them. The significance of HRV was first 
recognized in 1965 when Hon and Lee [18] reported an associ-
ation with fetal distress. This measurement is noninvasive and 
is easy to perform, so many studies were conducted using HRV. 
In 1996, a task force of the European Society of Cardiology and 
the North American Society of Pacing Electrophysiology stan-
dardized its measurement and interpretation [10]. Many previ-
ous studies utilized HRV analysis to evaluate ANS influence in 
various urologic disorders, including erectile dysfunction [19], 
chronic prostatitis [20], and female urinary incontinence [21]. 
Of the many HRV components, the LF component is consid-
ered to be a quantitative marker of sympathetic modulation; ef-
ferent vagal activity is a major contributor to the HF compo-
nent. Thus, the LF/HF ratio is considered to be a marker that 
mirrors the balance of sympathetic and parasympathetic ner-
vous activities, reflecting sympathetic modulation [10]. Al-
though the LF/HF ratio is a good marker of ANS activity, there 
are no cutoff values to identify sympathetic hyperactivity. To 
overcome this pitfall, we performed a pilot study (unpublished 
data) to identify the normal value of the LF/HF ratio in elderly 
men without LUTS. With the approval of the institutional re-
view board of Ajou University School of Medicine, 118 healthy 
volunteers from a health promotion center were included in the 
study and provided informed consent. They were men between 
the ages of 40 and 70 years, with a total IPSS lower than 8. HRV 
was measured in the same manner as in this study, and a cutoff 
value was derived to identify sympathetic hyperactivity. 
 Alfuzosin is an appropriate treatment agent for patients with 
BPH with acceptable safety profiles [22]. In this study, alfuzosin 
relieved LUTS regardless of sympathetic activity. Choi et al. [8] 
had previously performed an HRV analysis in healthy men and 
men with LUTS. They found that men with LUTS showed low-
er HF than healthy men and that patients with voiding symp-
tom-predominant LUTS had a higher LF/HF ratio compared 
to patients with storage symptom predominant LUTS. We hy-
pothesized that there would be difference in treatment out-
comes according to sympathetic activity, but our study results 
demonstrate similar profiles of treatment efficacy. Alfuzosin is 
an selective α1-blocker, but it failed to show any receptor selec-
tivity for α1 receptor subtypes [23,24]. This lack of subtype se-
lectivity may be a reason to disregard differences in sympathetic 
activity. Other clinically available α-blockers, such as tamsulo-
sin and silodosin, have specific selectivity for α1 receptor sub-
types, and their efficacy could be affected by sympathetic activi-
ty differences. Additional studies using these drugs could pro-
vide further evidence to fully describe their effects. 
 There are some limitations in our study. Since there is no re-
liable standard value to identify sympathetic hyperactivity in el-
derly Korean men, we performed a pilot study to identify crite-
ria for sympathetic hyperactivity in men. Although the number 
of men included in the pilot study was relatively small and a 
comparison with LUTS patients was not performed, we think 
the selected criteria in this study is valuable because it was de-
rived from a similar population as the study subjects. HRV was 
measured at an outpatient clinic, and there is some possibility 
that those hectic and crowded circumstances could influence 
HRV results. To exclude this possibility, we used an isolated 
room to measure HRV and restricted substances that could af-
fect sympathetic activity. 
 Most men with symptomatic BPH could be treated with 
α-blockers, but there are many other patients who do not re-
ceive any benefits from the current medications. For BPH pa-
tients who have shown a poor response to the current treat-
ments, identifying ANS dysfunction using HRV analysis could 
help gain a comprehensive understanding of treatment alterna-
tives.
 In conclusion, alfuzosin exhibited a good treatment effect re-
gardless of sympathetic activity, as measured by HRV. However, 
patient satisfaction regarding this treatment was lower in the 
HSA group. Sympathetic hyperactivity may be a factor to pre-
dict treatment satisfaction, but further studies are necessary. 
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